Project Grant R01CA297448
- The National Cancer Institute (NCI) awarded a $4,236,812 Project Grant under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393) to Children's Hospital Los Angeles (CHLA). The grant, effective September 10, 2025 through August 31, 2029, will fund a study to evaluate the use of a patient navigation intervention to improve transition outcomes for young adult survivors of childhood cancer, particularly those from low socioeconomic status and underinsured/uninsured...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $734,942 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The project, titled "Aging, DNA Methylation, and Incident Cardiovascular Disease in Breast Cancer Survivors," aims to generate new blood DNA methylation data and conduct research to better...
- The National Cancer Institute (NCI) has awarded a Cooperative Agreement totaling $1,059,908 to St. Jude Children's Research Hospital Inc. under the Cancer Cause and Prevention Research program (CFDA 93.393). This funding supports the St. Jude Lifetime Cohort (SJLIFE) study, an unparalleled longitudinal research initiative established in 2007 to investigate health outcomes and premature mortality among over 10,000 survivors of childhood and adolescent cancer. Key products and services provided...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a "Hybrid Type I Cluster Randomized Effectiveness-Implementation Trial of CARES" to address clinically significant levels of depression, pain, and fatigue experienced by over 18 million Americans living with cancer. The project aims to...
- This federal Project Grant award of $552,318 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of carbonic anhydrase as a cardioprotective target for mitigating the cardiotoxic effects of anthracycline chemotherapy drugs like doxorubicin. The research leverages human-induced pluripotent stem cell-derived cardiomyocytes to model anthracycline-induced cardiotoxicity and uses CRISPR interference/activation...
- This federal Project Grant award for $227,941, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), will fund the development and piloting of the "Cancer Care Companion" - an electronic health record (EHR) tool to improve information exchange and self-management for pediatric cancer patients and their families. The project aims to engage parents and pediatric oncology clinicians to co-develop the EHR-based communication tool, which will adapt...
- This federal Project Grant award for $279,411.00 was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant, awarded to the University of Washington on March 17, 2025, will support research to examine epigenetic changes during breast cancer treatment and their association with changes in exercise capacity and cardiac function. The study will leverage samples from the NCI-funded UPBEAT study to quantify DNA methylation as...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $185,693 to the Research Institute at Nationwide Children's Hospital to implement a digital health parent coaching intervention aimed at improving neurodevelopmental outcomes for young childhood cancer survivors in underserved communities. The project will be conducted over a 5-year period from March 1, 2025 to February 28, 2030. The Research Institute, a non-profit research...
- The National Cancer Institute (NCI) awarded a $851,463 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. The grant, awarded on September 1, 2025, will fund a 5-year research project to leverage electronic health record (EHR) data and community partnerships to understand the impacts of HIV and cancer stigma on cancer care delivery for people living with HIV in the Southeastern United States....
- The National Cancer Institute (NCI) awarded a $414,446 Project Grant to Colorado State University (CSU) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to conduct a 12-week group-based videoconference intervention aimed at increasing moderate to vigorous physical activity (MVPA) among cancer survivors. The goal is to examine the efficacy of this virtual exercise intervention in improving physical function, quality of life, and other health outcomes for this population....
The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.393 - Cancer Cause and Prevention Research to St. Jude Children's Research Hospital Inc. for the "Evaluation of Cardiovascular Health Outcomes among Survivors 2 (ECHOS-2)" study. The $772,418 grant, awarded on September 1, 2025, will test the efficacy of an eHealth-delivered intervention to improve adherence to cardiomyopathy screening among adult survivors of childhood cancer. The study aims to enroll 350 participants from the Childhood Cancer Survivor Study who received anthracycline chemotherapy or chest-directed radiation and have not undergone screening in the past 5 years. The project will evaluate the impact of the eHealth intervention on increasing screening rates compared to a control group, with the ultimate goal of reducing the risk of symptomatic heart failure in this high-risk population.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $21.3k | 9/5/25 | ||
| Not listed | $751.2k | 8/26/25 |